JATT II Acquisition Corp filings document the regulatory record of a Cayman Islands SPAC with Nasdaq-listed ordinary shares. The company’s Form 8-K disclosures report its initial public offering, ordinary-share capitalization, material definitive agreements, underwriter over-allotment arrangements and exchange listing under the symbol JATT.
The filing record also identifies governance and issuer-status matters, including emerging growth company status, Section 12(b) registration of the ordinary shares and other public-company disclosures associated with a blank-check company pursuing a business combination.
JATT II Acquisition Corp. seeks shareholder approval for its merger with Talawar Tx Inc.; the related share registration is for up to 7,650,000 shares of Post-Closing Company common stock. Under the proposed transaction, Talawar Merger Sub would merge into JATT, with JATT surviving as Talawar’s wholly owned subsidiary. At the Effective Time, JATT ordinary shares other than treasury, redeeming and dissenting shares convert one-for-one into Post-Closing Company shares. The transaction share consideration is defined as $120 million divided by $10.00 per share. Separately, PIPE investors agreed to buy 22,500,000 shares at $10.00 each, for $225 million in gross proceeds to the Post-Closing Company at closing.
Pro forma ownership assigns PIPE investors 52.71% of shares in the no-redemptions scenario and 61.33% under maximum redemptions. Closing requires approval of the business-combination and merger proposals and other conditions, including at least $125.0 million of Available Cash for Talawar after Company Expenses and JATT Expenses, and conditional Nasdaq listing approval. The listing condition may be waived by the parties and PIPE investors; if waived, the shares could be unlisted. JATT’s shareholder meeting is scheduled for December 2, 2026; redemption requests are due by 5:00 p.m. Eastern Time on November 30, 2026. The illustrative redemption price was approximately $10.19 per share as of November 3, 2026.
JATT II Acquisition Corp. (JATT) is the proposed business-combination partner in Talawar Therapeutics' announcement that it appointed Mittie Doyle, MD, and Susannah Gray to its board of directors. Talawar identifies TALA-125, an anti-IL-13 x anti-IL-18 bispecific, as its lead program and says it is advancing the candidate toward the clinic.
Dr. Doyle has more than 20 years of clinical-development experience across immunology, rheumatology and dermatology and is chief medical officer of Avalo Therapeutics. Gray has more than 30 years of biopharmaceutical finance and capital-markets experience; at Royalty Pharma, she oversaw more than $20 billion in financing and raised $2.0 billion in equity capital. The announcement presents the appointments as coming as Talawar prepares to become a public company through the proposed transaction with JATT.
JATT II Acquisition Corp. (JATT) received an amended Schedule 13D/A from its sponsor entity, JATT Ventures II L.P., and Dr. Someit Sidhu, primarily to correct Dr. Sidhu’s citizenship to the United Kingdom, with all other disclosures unchanged from the original filing. The reporting persons together beneficially own 1,800,000 ordinary shares, including 300,000 ordinary shares and 1,500,000 Founder Shares, representing 23.10% of the class based on 7,800,000 ordinary shares outstanding as of February 20, 2026. These holdings arose from the Sponsor’s purchase of 1,725,000 Founder Shares for $25,000, of which 225,000 were forfeited, and the purchase of 300,000 private placement shares for $3,000,000 in connection with the April 20, 2026 IPO. The Sponsor is subject to lock-up, voting, and registration rights arrangements, including agreements to vote in favor of a business combination and not seek redemption on its shares.
JATT II Acquisition Corp. (JATT) received a Schedule 13D reporting that JATT Ventures II L.P. (the sponsor) and Chief Executive Officer Dr. Someit Sidhu beneficially own 1,800,000 ordinary shares, representing 23.10% of the company’s 7,800,000 ordinary shares outstanding as of February 20, 2026.
The position consists of 300,000 ordinary shares purchased in a private placement at the IPO and 1,500,000 Founder Shares originally acquired for $25,000, with 225,000 founder shares previously forfeited. These private placement shares are subject to a lock-up until 30 days after a business combination, and the sponsor holds registration rights and has agreed to vote its shares in favor of a proposed business combination and not seek redemption.
JATT II Acquisition Corp. is pursuing a business combination with Talawar Tx Inc., whose CEO used a healthcare conference fireside chat to outline Talawar’s immunology and inflammation strategy and lead bispecific antibody TALA‑125 targeting IL‑13 and IL‑18 for atopic dermatitis.
Talawar plans a SAD/MAD Phase 1 study of TALA‑125 in healthy volunteers in Australia beginning around late 2026, followed by a randomized, placebo‑controlled Phase 2b trial in moderate to severe atopic dermatitis with a 16‑week primary readout targeted for the second half of 2028. Preclinical data in non‑human primates support extended half‑life, aiming for convenient dosing a few times per year, and no concerning immunogenicity signals have been seen so far, though human data will be required.
The discussion also highlights a previously announced PIPE financing of $225 million, plus potential additional capital from JATT’s approximately $60 million SPAC trust, which Talawar expects to fund operations past the Phase 2b readout and into 2029, and notes provisionally filed composition‑of‑matter IP for TALA‑125 that could extend to 2047.
JATT II Acquisition Corp. (JATT) filed a merger-related presentation describing its proposed business combination with immunology-focused biotech Talawar Tx Inc. Talawar is developing bispecific antibody therapies for immunology and inflammation diseases, led by TALA-125, an IL-13 x IL-18 bispecific for atopic dermatitis.
The companies describe a concurrent $225 million PIPE at $10.00 per share, which, together with JATT II’s trust assuming no redemptions, is expected to provide about $285 million in gross proceeds to the combined company and an expected cash runway into 2029. The merger and PIPE are expected to close in the fourth quarter of 2026, subject to customary conditions and JATT II shareholder approval, after which the combined company is expected to trade on the Nasdaq Capital Market under the ticker “TLWR”.
Talawar’s plan for TALA-125 includes a Phase 1 trial start in 1Q 2027, with an initial readout in 4Q 2027, and a Phase 2b proof-of-concept study starting in 1Q 2028 with data expected in 2H 2028. Additional bispecific programs, TALA-307 and TALA-711, are in earlier-stage discovery and preclinical development for broader immunologic indications.
ADAR1 Capital Management, LLC and Daniel Schneeberger report beneficial ownership of ordinary shares of JATT II Acquisition Corp. ADAR1-managed private investment funds hold 417,724 Ordinary Shares, and these shares may be deemed indirectly beneficially owned by both reporting persons.
The position represents 5.4% of JATT II’s Ordinary Shares, based on 7,800,000 shares outstanding as of June 30, 2026, as reported in the company’s quarterly report. Voting and dispositive power over the 417,724 shares is shared, with no sole voting or dispositive authority reported for either ADAR1 Capital Management or Mr. Schneeberger.
JATT II Acquisition Corp. received an amended Schedule 13G filing from Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz, collectively described as Filers. The Filers report beneficial ownership of 0.00 ordinary shares of JATT II Acquisition Corp., representing 0.0% of the class of ordinary shares with a par value of $0.0001 per share. They indicate no sole or shared voting or dispositive power over the shares and state that they own 5 percent or less of the class. The filing also includes a joint filing agreement among the Filers.
Great Point Partners, LLC, together with Dr. Jeffrey R. Jay, M.D. and Ms. Lillian Nordahl, reports beneficial ownership of 500,000 ordinary shares of JATT II Acquisition Corp., representing 6.23% of the class. These figures are based on 8,025,000 shares outstanding as reported by the issuer as of a prior Form 10-Q.
The 500,000 shares consist of 330,000 shares held by Biomedical Value Fund, L.P. and 170,000 shares held by Biomedical Offshore Value Fund, Ltd., for which Great Point acts as investment manager. Dr. Jay and Ms. Nordahl, in their roles at Great Point, share voting and dispositive power over these shares, while each disclaims beneficial ownership except to the extent of any pecuniary interest.
Atika Capital Management LLC and Brad Farber report beneficial ownership of JATT II Acquisition Corp. ordinary shares. They each report beneficial ownership of 400,000 shares, representing 5.1% of the outstanding class, with no sole voting or dispositive power.
All 400,000 shares are held by advisory clients of Atika Capital Management LLC, with Atika and Farber sharing voting and dispositive power over these positions. Each underlying advisory client is stated not to beneficially own more than 5% of JATT II Acquisition Corp.’s ordinary shares.